Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited
Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. In the genetically susceptible animal model, not only did blocking TNF-α reduce colitis but it also increased the anti-tumor activity of anti-cytotoxic T lymp...
Gespeichert in:
Veröffentlicht in: | Journal of the Turkish Academy of Dermatology 2020-09, Vol.14 (3), p.93-94 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. In the genetically susceptible animal model, not only did blocking TNF-α reduce colitis but it also increased the anti-tumor activity of anti-cytotoxic T lymphocyte-associated antigen-4 and PD-1 antibodies. [...]if moderate or severe psoriatic lesions develop during nivolumab therapy, SSZ therapy cannot only treat the skin lesions but may also increase nivolumab’s anti-tumor effect. Authorship Contributions Surgical and Medical Practices: G.O., K.N.P., C.D., Concept: G.O., K.N.P., C.D., Design: G.O., K.N.P., C.D., Data Collection or Processing: G.O., K.N.P., C.D., Analysis or Interpretation: G.O., K.N.P., C.D., Literature Search: G.O., K.N.P., C.D., Writing: G.O., K.N.P., C.D. Conflict of Interest: No conflict of interest was declared by the authors. |
---|---|
ISSN: | 1307-394X 1307-394X |
DOI: | 10.4274/jtad.galenos.2020.13007 |